T cells influence cytotoxicity of venetoclax and azacytidine in AML. (A) PBMCs obtained from 3 patients with AML (837637, 140012, and 846317) were depleted or enriched for autologous T cells, followed by treatment with increasing concentrations of venetoclax (0-500 nM) and azacytidine (0-3000 nM) (1 day for 140012 or 2 days for 837637 and 846317). The cells were stained with Annexin V, and the relative number of viable AML cells was determined by flow cytometry. (B) AML cells obtained from patients (110866 and 118313) before venetoclax and azacytidine treatment were cultured with or without autologous T cells isolated from the same patient with AML before or on day 4 of venetoclax and azacytidine treatment (day 4). The cells were stained with Annexin V, and the relative numbers of viable AML cells was determined by flow cytometry. Student t test or 2-way analysis of variance was used for statistics. *P < .05; **P < .01; ***P < .001.